Samuel A Bozzette
Overview
Explore the profile of Samuel A Bozzette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1224
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lachiewicz A, Shah M, Der T, Cyr D, Al-Khalidi H, Lindsell C, et al.
CHEST Crit Care
. 2024 Nov;
2(4).
PMID: 39610848
Background: Coronavirus disease 2019 (COVID-19) pneumonia requires considerable healthcare resources. Research Objective: Examine if a single dose of infliximab or abatacept, in addition to remdesivir and steroids, decreased resource utilization...
2.
Lin D, Wang J, Anstrom K, LaVange L, Wen J, Bozzette S, et al.
Int J Infect Dis
. 2024 Jul;
146:107168.
PMID: 38977241
A randomized, double-blind, placebo-controlled clinical trial was conducted to investigate the efficacy of infliximab, abatacept, and cenicriviroc in treating patients hospitalized with COVID-19. The patient's clinical status was assessed daily...
3.
Powderly W, LaVange L, Bozzette S
JAMA
. 2023 Dec;
330(21):2123.
PMID: 38051329
No abstract available.
4.
OHalloran J, Ko E, Anstrom K, Kedar E, McCarthy M, Panettieri Jr R, et al.
JAMA
. 2023 Jul;
330(4):328-339.
PMID: 37428480
Importance: Immune dysregulation contributes to poorer outcomes in COVID-19. Objective: To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia. Design, Setting, And...
5.
Ko E, Anstrom K, Panettieri R, Lachiewicz A, Maillo M, OHalloran J, et al.
medRxiv
. 2022 Oct;
PMID: 36203544
Background: We investigated whether abatacept, a selective costimulation modulator, provides additional benefit when added to standard-of-care for patients hospitalized with Covid-19. Methods: We conducted a master protocol to investigate immunomodulators...
6.
OHalloran J, Kedar E, Anstrom K, McCarthy M, Ko E, Nunez P, et al.
medRxiv
. 2022 Sep;
PMID: 36172138
Background: Immune dysregulation contributes to poorer outcomes in severe Covid-19. Immunomodulators targeting various pathways have improved outcomes. We investigated whether infliximab provides benefit over standard of care. Methods: We conducted...
7.
Duff S, Hasbun R, Balada-Llasat J, Zimmer L, Bozzette S, Ginocchio C
Infection
. 2019 May;
47(6):945-953.
PMID: 31111325
Purpose: Many patients with suspected meningitis do not require hospitalization yet are admitted, often resulting in unnecessary care and additional cost. We assessed the possible economic impact of a rapid...
8.
Duff S, Hasbun R, Ginocchio C, Balada-Llasat J, Zimmer L, Bozzette S
Future Microbiol
. 2018 Jan;
13:617-629.
PMID: 29316801
Aim: We assessed the possible economic impact of a rapid test in pediatric patients with suspected community-acquired meningitis/encephalitis. Materials & Methods: Modeling simulated diagnosis, clinical decisions, resource use/costs of standard...
9.
Balk R, Kadri S, Cao Z, Robinson S, Lipkin C, Bozzette S
Chest
. 2017 Jul;
152(1):219-220.
PMID: 28693772
No abstract available.
10.
Balk R, Kadri S, Cao Z, Robinson S, Lipkin C, Bozzette S
Chest
. 2016 Aug;
151(1):23-33.
PMID: 27568580
Background: There is a growing use of procalcitonin (PCT) to facilitate the diagnosis and management of severe sepsis. We investigated the impact of one to two PCT determinations on ICU...